Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial
- PMID: 28402516
- PMCID: PMC6257031
- DOI: 10.1093/neuros/nyx123
Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial
Abstract
Background: Minimally invasive thrombolytic evacuation of intracerebral hematoma is being investigated in the ongoing phase III clinical trial of Minimally Invasive Surgery plus recombinant Tissue plasminogen activator for Intracerebral hemorrhage Evacuation (MISTIE III).
Objective: To assess the accuracy of catheter placement and efficacy of hematoma evacuation in relation to surgical approach and surgeon experience.
Methods: We performed a trial midpoint interim assessment of 123 cases that underwent the surgical procedure. Accuracy of catheter placement was prospectively assessed by the trial Surgical Center based on prearticulated criteria. Hematoma evacuation efficacy was evaluated based on absolute volume reduction, percentage hematoma evacuation, and reaching the target end-of-treatment volume of <15 mL. One of 3 surgical trajectories was used: anterior (A), posterior (B), and lobar (C). Surgeons were classified based on experience with the MISTIE procedure as prequalified, qualified with probation, and fully qualified.
Results: The average hematoma volume was 49.7 mL (range 20.0-124), and the mean evacuation rate was 71% (range 18.4%-99.8%). First placed catheters were 58% in good position, 28% suboptimal (but suitable to dose), and 14% poor (requiring repositioning). Posterior trajectory (B) was associated with significantly higher rates of poor placement (35%, P = .01). There was no significant difference in catheter placement accuracy among surgeons of varying experience. Hematoma evacuation efficacy was not significantly different among the 3 surgical approaches or different surgeons' experience.
Conclusion: Ongoing surgical education and quality monitoring in MISTIE III have resulted in consistent rates of hematoma evacuation despite technical challenges with the surgical approaches and among surgeons of varying experience.
Keywords: Alteplase; Intracerebral hemorrhage; MISTIE; Minimally invasive; Tissue plasminogen activator.
Copyright © 2017 by the Congress of Neurological Surgeons
Figures
Similar articles
-
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.Neurosurgery. 2019 Jun 1;84(6):1157-1168. doi: 10.1093/neuros/nyz077. Neurosurgery. 2019. PMID: 30891610 Free PMC article. Clinical Trial.
-
A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III).Int J Stroke. 2019 Jul;14(5):548-554. doi: 10.1177/1747493019839280. Epub 2019 Apr 3. Int J Stroke. 2019. PMID: 30943878 Free PMC article. Clinical Trial.
-
Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials.Oper Neurosurg (Hagerstown). 2020 Dec 15;20(1):98-108. doi: 10.1093/ons/opaa306. Oper Neurosurg (Hagerstown). 2020. PMID: 33313847 Free PMC article.
-
Modern Approaches to Evacuating Intracerebral Hemorrhage.Curr Cardiol Rep. 2018 Oct 11;20(12):132. doi: 10.1007/s11886-018-1078-4. Curr Cardiol Rep. 2018. PMID: 30311010 Review.
-
Future perspectives on the fibrinolytic therapy of intracerebral hemorrhages.Cent Nerv Syst Agents Med Chem. 2011 Jun 1;11(2):150-6. doi: 10.2174/187152411796011367. Cent Nerv Syst Agents Med Chem. 2011. PMID: 21521167 Review.
Cited by
-
Continuous Tissue Plasminogen Activator Infusion Using a Minimally Invasive Irrigating Catheter for the Treatment of Intraparenchymal Hemorrhage Within the Basal Ganglia: Case Reports.Oper Neurosurg (Hagerstown). 2022 Dec 1;23(6):e387-e391. doi: 10.1227/ons.0000000000000408. Epub 2022 Sep 14. Oper Neurosurg (Hagerstown). 2022. PMID: 36227254 Free PMC article.
-
Neuronal ferroptosis after intracerebral hemorrhage.Front Mol Biosci. 2022 Aug 5;9:966478. doi: 10.3389/fmolb.2022.966478. eCollection 2022. Front Mol Biosci. 2022. PMID: 35992267 Free PMC article. Review.
-
Neuroendoscopic-assisted versus mini-open craniotomy for hypertensive intracerebral hemorrhage: a retrospective analysis.BMC Surg. 2022 May 14;22(1):188. doi: 10.1186/s12893-022-01642-8. BMC Surg. 2022. PMID: 35568858 Free PMC article.
-
Irregular-Shaped Hematoma Predicts Postoperative Rehemorrhage After Stereotactic Minimally Invasive Surgery for Intracerebral Hemorrhage.Front Neurol. 2022 Mar 11;13:727702. doi: 10.3389/fneur.2022.727702. eCollection 2022. Front Neurol. 2022. PMID: 35359642 Free PMC article.
-
Recent advances and perspectives of postoperative neurological disorders in the elderly surgical patients.CNS Neurosci Ther. 2022 Apr;28(4):470-483. doi: 10.1111/cns.13763. Epub 2021 Dec 3. CNS Neurosci Ther. 2022. PMID: 34862758 Free PMC article. Review.
References
-
- Mendelow AD, Gregson BA, Fernandes HM et al. . Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365(9457):387-397. - PubMed
-
- Morgenstern LB, Demchuk AM, Kim DH, Frankowski RF, Grotta JC. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology. 2001;56(10):1294-1299. - PubMed
-
- Zuccarello M, Brott T, Derex L et al. . Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study. Stroke. 1999;30(9):1833-1839. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources